Sanofi underscores pipeline advances, setbacks

Sanofi-Aventis had some good news and some bad news to deliver to analysts during its first pipeline update in two years. On the down side: Its Alzheimer's drug Xaliproden failed late-stage trials. But its antidepressant saredutant passed its late-stage trials, setting up a schedule to file for approval in Europe and the U.S. next year. Another antidepressant, Amibegron, met its primary goal in only one out of four clinical trials.

Sanofi research chief Marc Cluzel (photo) underscored his commitment to the obesity drug Acomplia, though he acknowledged that the drug now faces a long delay in the U.S. Sanofi also announced that it has 48 therapies in late-stage development and expects to file on 31 of them by the end of 2010.

- see Sanofi's release on the pipeline
- read the AP report from Paris

Related Articles:
What's Warren Buffett buying now? Report
Sanofi shares plunge on Acomplia rejection. Report
Sanofi shares slide as FDA delays Acomplia-again. Report
Sanofi signs stem cell pact in China. Report

Suggested Articles

Bristol Myers Squibb is teaming up with Repare Therapeutics to find new synthetic lethality targets in a deal that could be worth billions.

Biotech Orpheris has been given the FDA go-ahead for a phase 2 aimed at calming the cytokine storm sometimes caused by COVID-19.

PureTech plans to start a trial in the emerging population of patients who survive COVID-19 only to suffer lasting damage in the third quarter.